Ovid's snapshot of broad efficacy data for their PhII Angelman syndrome trial can't stop a rout -- shares crushed
Ovid Therapeutics $OVID says it picked up a snapshot of broad, positive efficacy in its Phase II study of a new drug for rare cases …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
